{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T10:17:15Z","timestamp":1648894635559},"reference-count":93,"publisher":"Georg Thieme Verlag KG","issue":"02","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pneumologie"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Die pulmonale Hypertonie (PH) ist eine regelm\u00e4\u00dfige Komplikation von Kollagenosen und wird zudem im Zusammenhang mit Lungen- und Linksherzerkrankungen diagnostiziert. <\/jats:p><jats:p>Die korrekte Differenzierung und Klassifikation der PH ist essenziell, um Therapien m\u00f6glichst zielgerichtet einsetzen zu k\u00f6nnen und ein Vorenthalten von wichtigen Therapien ebenso zu vermeiden wie eine \u00dcbertherapie.<\/jats:p><jats:p>Bei den Kollagenosen umfasst die Differenzialdiagnostik und Klassifikation die Differenzierung innerhalb der assoziierten pulmonalarteriellen Hypertonie (APAH) Gruppe 1, aber auch, Klassifikationsgruppen \u00fcbergreifend, die Gruppe 2 (mit f\u00fchrender linkskardialer Beteiligung), Gruppe 3 (mit f\u00fchrender parenchymat\u00f6ser Lungenerkrankung), Gruppe 4 (chronisch thromboembolische PH) und letztlich die Gruppe 5 (z.\u200aB. bei terminaler Niereninsuffizienz und Dialysepflicht). <\/jats:p><jats:p>\u00c4hnliches trifft auch auf die zunehmend \u00e4lteren Patienten zu, die mit einer PAH diagnostiziert werden und Komorbidit\u00e4ten aufweisen, die entweder selbst eine PH hervorrufen k\u00f6nnen oder als Komorbidit\u00e4ten einer echten PAH auftreten. <\/jats:p><jats:p>Die abnehmende Trennsch\u00e4rfe zwischen den einzelnen PH-Gruppen erschwert die korrekte Klassifikation und stellt eine gro\u00dfe klinische Herausforderung dar. <\/jats:p><jats:p>Auf dem Boden unterschiedlicher klinischer Szenarien wird im vorliegenden Artikel die Differenzialdiagnostik der PH sowohl bei Kollagenosen als auch bei chronischen Linksherz- und Lungenerkrankungen aufgearbeitet und objektive Kriterien vorgestellt, die diese Differenzierung erleichtern. <\/jats:p>","DOI":"10.1055\/a-1204-3248","type":"journal-article","created":{"date-parts":[[2021,2,14]],"date-time":"2021-02-14T05:08:05Z","timestamp":1613279285000},"page":"122-137","source":"Crossref","is-referenced-by-count":0,"title":["Differenzialdiagnostik der pulmonalen Hypertonie am Beispiel der Kollagenose assoziierten PAH im Kontext chronischer Lungen- und Linksherzerkrankungen"],"prefix":"10.1055","volume":"75","author":[{"given":"H. H.","family":"Leuchte","sequence":"additional","affiliation":[{"name":"Klinik der Barmherzigen Schwestern, Krankenhaus Neuwittelsbach, Lehrkrankenhaus der LMU M\u00fcnchen, Mitglied des DZL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Halank","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Carl Gustav Carus, Medizinische Klinik 1, Bereich Pneumologie, Dresden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Held","sequence":"additional","affiliation":[{"name":"Klinikum W\u00fcrzburg Mitte, Standort Missioklinik, Medizinische Klinik mit Schwerpunkt Pneumologie und Beatmungsmedizin, W\u00fcrzburg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Borst","sequence":"additional","affiliation":[{"name":"Medizinische Klinik 1 Caritas-Krankenhaus Bad Mergentheim gemeinn\u00fctzige GmbH, Bad Mergentheim"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Ewert","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsmedizin Greifswald. Klinik f\u00fcr Innere Medizin B, Bereich Pneumologie, Greifswald"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Klose","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf, Abteilung f\u00fcr Pneumologie, Hamburg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. J.","family":"Lange","sequence":"additional","affiliation":[{"name":"Uniklinik Regensburg, Klinik f\u00fcr Innere Medizin II, Bereich Pneumologie, Regensburg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. J.","family":"Meyer","sequence":"additional","affiliation":[{"name":"Lungenzentrum M\u00fcnchen (Bogenhausen-Harlaching), M\u00fcnchen Klinik gGmbH, M\u00fcnchen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Skowasch","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Bonn, Medizinische Klinik II, Sektion Pneumologie, Bonn"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Wilkens","sequence":"additional","affiliation":[{"name":"Pneumologie, Uniklinik Homburg, Homburg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.-J.","family":"Seyfarth","sequence":"additional","affiliation":[{"name":"Bereich Pneumologie, Universit\u00e4tsklinikum Leipzig, Leipzig"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2021,2,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1183\/13993003.01032-2015","article-title":"2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)","volume":"46","author":"N Galie","year":"2015","journal-title":"Eur Respir J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01914-2018","article-title":"Pulmonary hypertension in chronic lung disease and hypoxia","author":"S D Nathan","year":"2019","journal-title":"Eur Respir J"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01897-2018","article-title":"Pulmonary hypertension due to left heart disease","author":"J L Vachiery","year":"2019","journal-title":"Eur Respir J"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.ijcard.2012.10.026","article-title":"Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry","volume":"168","author":"M M Hoeper","year":"2013","journal-title":"Int J Cardiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","author":"G Simonneau","year":"2019","journal-title":"Eur Respir J"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1164\/rccm.200510-1668OC","article-title":"Pulmonary arterial hypertension in France: results from a national registry","volume":"173","author":"M Humbert","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1161\/CIRCULATIONAHA.109.898122","article-title":"Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL)","volume":"122","author":"R L Benza","year":"2010","journal-title":"Circulation"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.0740-2017","article-title":"Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model","author":"M M Hoeper","year":"2017","journal-title":"Eur Respir J"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.chest.2019.02.004","article-title":"Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC\/ERS-Based Risk Assessment Strategies","volume":"156","author":"R L Benza","year":"2019","journal-title":"Chest"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1378\/chest.10-0260","article-title":"Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype","volume":"138","author":"L Chung","year":"2010","journal-title":"Chest"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s10067-013-2307-2","article-title":"Prevalence of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review of the literature","volume":"32","author":"X Yang","year":"2013","journal-title":"Clin Rheumatol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3899\/jrheum.150382","article-title":"Vasoactive Therapy in Systemic Sclerosis: Real-life Therapeutic Practice in More Than 3000 Patients","volume":"43","author":"P Moinzadeh","year":"2016","journal-title":"J Rheumatol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1002\/art.38029","article-title":"Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis","volume":"65","author":"G Lefevre","year":"2013","journal-title":"Arthritis Rheum"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2013-203301","article-title":"Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study","volume":"73","author":"J G Coghlan","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s13075-015-0673-7","article-title":"Stress Doppler echocardiography for early detection of systemic sclerosis-associated pulmonary arterial hypertension","volume":"17","author":"C Nagel","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0023-2019","article-title":"Screening for pulmonary arterial hypertension in systemic sclerosis","author":"J Weatherald","year":"2019","journal-title":"Eur Respir Rev"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijcard.2018.08.083","article-title":"Definition, clinical classification and initial diagnosis of pulmonary hypertension: Updated recommendations from the Cologne Consensus Conference 2018","volume":"272S","author":"G Kovacs","year":"2018","journal-title":"Int J Cardiol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1136\/heartjnl-2016-309981","article-title":"Cardiopulmonary exercise testing for detecting pulmonary arterial hypertension in systemic sclerosis","volume":"103","author":"D Dumitrescu","year":"2017","journal-title":"Heart"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1183\/09031936.00145608","article-title":"Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review","volume":"34","author":"G Kovacs","year":"2009","journal-title":"Eur Respir J"},{"key":"ref20","first-page":"1367","article-title":"Hemodynamic Definition of Pulmonary Hypertension: Commentary on the Proposed Change by the 6th World Symposium on Pulmonary Hypertension","volume":"144","author":"S Rosenkranz","year":"2019","journal-title":"Dtsch Med Wochenschr"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/art.37838","article-title":"Borderline mean pulmonary artery pressure in patients with systemic sclerosis: transpulmonary gradient predicts risk of developing pulmonary hypertension","volume":"65","author":"C J Valerio","year":"2013","journal-title":"Arthritis Rheum"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01197-2017","article-title":"Incidence of pulmonary hypertension and determining factors in patients with systemic sclerosis","author":"J G Coghlan","year":"2018","journal-title":"Eur Respir J"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1093\/rheumatology\/kex435","article-title":"Frequencies of borderline pulmonary hypertension before and after the DETECT algorithm: results from a prospective systemic sclerosis cohort","volume":"57","author":"A M Hoffmann-Vold","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/art.33460","article-title":"Pulmonary arterial hypertension therapy may be safe and effective in patients with systemic sclerosis and borderline pulmonary artery pressure","volume":"64","author":"G Kovacs","year":"2012","journal-title":"Arthritis Rheum"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.humpath.2006.11.022","article-title":"Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases","volume":"38","author":"P Dorfmuller","year":"2007","journal-title":"Hum Pathol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.bpg.2013.06.016","article-title":"Liver abnormalities in connective tissue diseases","volume":"27","author":"M De Santis","year":"2013","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1097\/MEG.0b013e32833ab83a","article-title":"Gastric variceal bleeding uncovering a rare association of CREST syndrome, primary biliary cirrhosis, nodular regenerative hyperplasia and pulmonary hypertension","volume":"22","author":"E Riviere","year":"2010","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3899\/jrheum.170292","article-title":"Nodular Regenerative Hyperplasia of the Liver: A Rare Vascular Complication in Systemic Sclerosis","volume":"45","author":"L Graf","year":"2018","journal-title":"J Rheumatol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1183\/09031936.00091212","article-title":"High prevalence of occult left heart disease in scleroderma-pulmonary hypertension","volume":"42","author":"B D Fox","year":"2013","journal-title":"Eur Respir J"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.berh.2016.03.004","article-title":"Connective tissue disease-related pulmonary arterial hypertension","volume":"30","author":"V Thakkar","year":"2016","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1136\/ard.2008.103382","article-title":"Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis","volume":"69","author":"Y Allanore","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.acvd.2009.06.009","article-title":"Heart involvement in systemic sclerosis: evolving concept and diagnostic methodologies","volume":"103","author":"C Meune","year":"2010","journal-title":"Arch Cardiovasc Dis"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/art.41153","article-title":"Using Autoantibodies and Cutaneous Subset to Develop Outcome-Based Disease Classification in Systemic Sclerosis","volume":"72","author":"S I Nihtyanova","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S2213-2600(15)00542-1","article-title":"Treatment of pulmonary hypertension","volume":"4","author":"M M Hoeper","year":"2016","journal-title":"Lancet Respir Med"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1161\/CIRCULATIONAHA.110.983866","article-title":"Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study","volume":"124","author":"M Guazzi","year":"2011","journal-title":"Circulation"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1161\/CIRCULATIONAHA.113.001458","article-title":"Left Ventricular Systolic Dysfunction Associated With Pulmonary Hypertension Riociguat Trial Study G. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study","volume":"128","author":"D Bonderman","year":"2013","journal-title":"Circulation"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1093\/eurheartj\/ehv336","article-title":"Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial","volume":"36","author":"E S Hoendermis","year":"2015","journal-title":"Eur Heart J"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/eurheartj\/ehx700","article-title":"Sildenafil for Improving Outcomes after VCi. Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial","volume":"39","author":"J Bermejo","year":"2018","journal-title":"Eur Heart J"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01886-2017","article-title":"Macitentan in pulmonary hypertension due to left ventricular dysfunction","author":"J L Vachiery","year":"2018","journal-title":"Eur Respir J"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1378\/chest.09-1140","article-title":"Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry","volume":"137","author":"D B Badesch","year":"2010","journal-title":"Chest"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1161\/CIRCULATIONAHA.110.015008","article-title":"Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry","volume":"124","author":"J Pepke-Zaba","year":"2011","journal-title":"Circulation"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1093\/eurheartj\/ehv512","article-title":"Left ventricular heart failure and pulmonary hypertension","volume":"37","author":"S Rosenkranz","year":"2016","journal-title":"Eur Heart J"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1378\/chest.08-2784","article-title":"Misclassification of pulmonary hypertension due to reliance on pulmonary capillary wedge pressure rather than left ventricular end-diastolic pressure","volume":"136","author":"S D Halpern","year":"2009","journal-title":"Chest"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.0578-2017","article-title":"An official European Respiratory Society statement: pulmonary haemodynamics during exercise","author":"G Kovacs","year":"2017","journal-title":"Eur Respir J"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.117.004450","article-title":"What We Talk About When We Talk About the Wedge Pressure","author":"B A Houston","year":"2017","journal-title":"Circ Heart Fail"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/ejhf.675","article-title":"Determinants and prognostic implications of the negative diastolic pulmonary pressure gradient in patients with pulmonary hypertension due to left heart disease","volume":"19","author":"A I Nagy","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1001\/jamacardio.2018.0318","article-title":"Comparing Pulmonary Arterial Wedge Pressure and Left Ventricular End Diastolic Pressure for Assessment of Left-Sided Filling Pressures","volume":"3","author":"Y NV Reddy","year":"2018","journal-title":"JAMA Cardiol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jacc.2016.05.047","article-title":"Pre-Capillary, Combined, and Post-Capillary Pulmonary Hypertension: A Pathophysiological Continuum","volume":"68","author":"C F Opitz","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.healun.2019.09.010","article-title":"Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: Results from the AMBITION trial","volume":"38","author":"V V McLaughlin","year":"2019","journal-title":"J Heart Lung Transplant"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1161\/CIRCULATIONAHA.112.111302","article-title":"Hemodynamic responses to rapid saline loading: the impact of age, sex, and heart failure","volume":"127","author":"N Fujimoto","year":"2013","journal-title":"Circulation"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1161\/CIRCULATIONAHA.112.000667","article-title":"Pulmonary vascular hemodynamic response to exercise in cardiopulmonary diseases","volume":"128","author":"G D Lewis","year":"2013","journal-title":"Circulation"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1161\/CIRCHEARTFAILURE.114.001731","article-title":"Differential hemodynamic effects of exercise and volume expansion in people with and without heart failure","volume":"8","author":"M J Andersen","year":"2015","journal-title":"Circ Heart Fail"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/ejhf.198","article-title":"Exercise haemodynamics may unmask the diagnosis of diastolic dysfunction among patients with pulmonary hypertension","volume":"17","author":"E Maor","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1161\/CIRCULATIONAHA.117.031608","article-title":"Global Pulmonary Vascular Remodeling in Pulmonary Hypertension Associated With Heart Failure and Preserved or Reduced Ejection Fraction","volume":"137","author":"A U Fayyaz","year":"2018","journal-title":"Circulation"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01889-2018","article-title":"Risk stratification and medical therapy of pulmonary arterial hypertension","author":"N Galie","year":"2019","journal-title":"Eur Respir J"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1164\/rccm.200308-1142OC","article-title":"Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension","volume":"170","author":"H H Leuchte","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1164\/rccm.200401-006OC","article-title":"Severe pulmonary hypertension and chronic obstructive pulmonary disease","volume":"172","author":"A Chaouat","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.jcf.2013.12.004","article-title":"Impact of pulmonary hypertension on survival in patients with cystic fibrosis undergoing lung transplantation: an analysis of the UNOS registry","volume":"13","author":"D Hayes Jr","year":"2014","journal-title":"J Cyst Fibros"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.athoracsur.2015.06.024","article-title":"Influence of Pulmonary Hypertension on Patients With Idiopathic Pulmonary Fibrosis Awaiting Lung Transplantation","volume":"101","author":"D Hayes Jr","year":"2016","journal-title":"Ann Thorac Surg"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3109\/15412555.2015.1043425","article-title":"Prevalence of Pulmonary Hypertension and its Influence on Survival in Patients With Advanced Chronic Obstructive Pulmonary Disease Prior to Lung Transplantation","volume":"13","author":"D Hayes Jr","year":"2016","journal-title":"COPD"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1378\/chest.127.5.1531","article-title":"Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation","volume":"127","author":"G Thabut","year":"2005","journal-title":"Chest"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1378\/chest.127.5.1480","article-title":"Severe pulmonary hypertension in COPD: is it a distinct disease?","volume":"127","author":"E Weitzenblum","year":"2005","journal-title":"Chest"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1164\/ajrccm.159.1.9803117","article-title":"Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease","volume":"159","author":"R Kessler","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1378\/chest.06-1466","article-title":"Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis","volume":"131","author":"K Hamada","year":"2007","journal-title":"Chest"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1378\/chest.11-3241","article-title":"Comorbid conditions and outcomes in patients with pulmonary arterial hypertension: a REVEAL registry analysis","volume":"144","author":"A D Poms","year":"2013","journal-title":"Chest"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"2045894020914851","DOI":"10.1177\/2045894020914851","article-title":"Idiopathic pulmonary arterial hypertension and co-existing lung disease: is this a new phenotype?","volume":"10","author":"A J Peacock","year":"2020","journal-title":"Pulm Circ"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1164\/rccm.201407-1382OC","article-title":"Pulmonary hypertension in cystic fibrosis with advanced lung disease","volume":"190","author":"D Hayes Jr","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1164\/rccm.200510-1545OC","article-title":"Brain natriuretic peptide is a prognostic parameter in chronic lung disease","volume":"173","author":"H H Leuchte","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ijcard.2018.08.043","article-title":"Pulmonary hypertension due to lung diseases: Updated recommendations from the Cologne Consensus Conference 2018","volume":"272S","author":"H Olschewski","year":"2018","journal-title":"Int J Cardiol"},{"key":"ref70","first-page":"1596","article-title":"Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. Reply","volume":"381","author":"O Distler","year":"2019","journal-title":"N Engl J Med"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1183\/13993003.01537-2014","article-title":"Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction","volume":"46","author":"G Raghu","year":"2015","journal-title":"Eur Respir J"},{"issue":"S 01","key":"ref72","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/1756-0500-6-S1-S2","article-title":"Clinical case: Combined pulmonary fibrosis and emphysema with pulmonary hypertension -- clinical management","volume":"6","author":"V Cottin","year":"2013","journal-title":"BMC Res Notes"},{"key":"ref73","first-page":"82","article-title":"Macitentan and pulmonary arterial hypertension","volume":"370","author":"T Pulido","year":"2014","journal-title":"N Engl J Med"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the treatment of pulmonary arterial hypertension","volume":"369","author":"H A Ghofrani","year":"2013","journal-title":"N Engl J Med"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1177\/2397198318764780","article-title":"Patients with systemic sclerosis-associated pulmonary arterial hypertension express a genomic signature distinct from patients with interstitial lung disease","volume":"3","author":"M Moll","year":"2018","journal-title":"J Scleroderma Relat Disord"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/1756-185X.13001","article-title":"Pulmonary hypertension in connective tissue diseases: an update","volume":"20","author":"R Aithala","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"ref77","first-page":"46","article-title":"12-Monats-Pr\u00e4valenz der bekannten chronisch obstruktiven Lungenerkrankung (COPD) in Deutschland","author":"C SHKRS-N","year":"2017","journal-title":"J Health Monitoring"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1164\/rccm.201801-0095PP","article-title":"Pulmonary Vascular Involvement in Chronic Obstructive Pulmonary Disease. Is There a Pulmonary Vascular Phenotype?","volume":"198","author":"G Kovacs","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1161\/01.CIR.0000091409.53101.E8","article-title":"Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease","volume":"108","author":"S Eddahibi","year":"2003","journal-title":"Circulation"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1093\/eurheartj\/ehi291","article-title":"Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease","volume":"26","author":"F H Rutten","year":"2005","journal-title":"Eur Heart J"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1378\/chest.07-2685","article-title":"Left ventricular diastolic dysfunction in patients with COPD in the presence and absence of elevated pulmonary arterial pressure","volume":"133","author":"G C Funk","year":"2008","journal-title":"Chest"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.rmed.2013.05.001","article-title":"Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort","volume":"107","author":"J Miller","year":"2013","journal-title":"Respir Med"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.hlc.2013.08.003","article-title":"Lung function abnormalities are highly frequent in patients with heart failure and preserved ejection fraction","volume":"23","author":"R Andrea","year":"2014","journal-title":"Heart Lung Circ"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1513\/AnnalsATS.201403-125OC","article-title":"Evaluation of CLtIPSE. Identification of five chronic obstructive pulmonary disease subgroups with different prognoses in the ECLIPSE cohort using cluster analysis","volume":"12","author":"S I Rennard","year":"2015","journal-title":"Ann Am Thorac Soc"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1183\/09031936.00085612","article-title":"Haemodynamic responses to exercise in patients with COPD","volume":"41","author":"J M Hilde","year":"2013","journal-title":"Eur Respir J"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.2147\/COPD.S78180","article-title":"Pulmonary hemodynamic profile in chronic obstructive pulmonary disease","volume":"10","author":"K Portillo","year":"2015","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.rmed.2010.05.009","article-title":"Categorization and impact of pulmonary hypertension in patients with advanced COPD","volume":"104","author":"M J Cuttica","year":"2010","journal-title":"Respir Med"},{"key":"ref88","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.healun.2011.11.020","article-title":"Prevalence, predictors, and survival in pulmonary hypertension related to end-stage chronic obstructive pulmonary disease","volume":"31","author":"K H Andersen","year":"2012","journal-title":"J Heart Lung Transplant"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1183\/09031936.00079512","article-title":"Pulmonary hypertension in COPD: results from the ASPIRE registry","volume":"41","author":"J Hurdman","year":"2013","journal-title":"Eur Respir J"},{"key":"ref90","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1378\/chest.11-2798","article-title":"Ventilatory and cardiocirculatory exercise profiles in COPD: the role of pulmonary hypertension","volume":"142","author":"B G Boerrigter","year":"2012","journal-title":"Chest"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1164\/rccm.201811-2063OC","article-title":"Arterial Vascular Pruning, Right Ventricular Size, and Clinical Outcomes in Chronic Obstructive Pulmonary Disease. A Longitudinal Observational Study","volume":"200","author":"G R Washko","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"ref92","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1093\/rheumatology\/key095","article-title":"Prevalence, persistence and clinical correlations of classic and novel antiphospholipid antibodies in systemic lupus erythematosus","volume":"57","author":"T Marchetti","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"ref93","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3899\/jrheum.150451","article-title":"Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: Prevalence and Predictors","volume":"43","author":"G M Perez-Penate","year":"2016","journal-title":"J Rheumatol"}],"container-title":["Pneumologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1204-3248.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,14]],"date-time":"2021-02-14T05:09:35Z","timestamp":1613279375000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1204-3248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":93,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2021,2,12]]},"published-print":{"date-parts":[[2021,2]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1204-3248","relation":{},"ISSN":["0934-8387","1438-8790"],"issn-type":[{"value":"0934-8387","type":"print"},{"value":"1438-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]}}}